Dr.Chandra Prakash Prasad

DR. CHANDRA PRAKSH PRASAD, PhD, PGDBA (Operations), FSLSc

Associate Professor,

Department of Medical Oncology (Lab),

All India Institute of Medical Sciences (AIIMS),

Ansari Nagar, New Delhi-110029.

Tel: Off: 011-29575430

E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Webpage: https://researchchandra.wixsite.com/my-site-2

Orcid ID: orcid.org/0000-0002-4911-7483

Research ID: B-6404-2015

EMPLOYMENT HISTORY

1. 2020-07-01 to till now:  Associate Professor (Medical Oncology (Lab) at All India Institute of Medical Sciences: New Delhi, Delhi

2. 2016-11-09 to 2020-06-30:  Assistant Professor (Medical Oncology (Lab) at All India Institute of Medical Sciences: New Delhi, Delhi

3. 2014-03-01 to 2016-08-29: Laboratory Investigator (Experimental Pathology, Dept of Translational Medicine) at Lunds universitet Medicinska fakulteten: Malmo, Skane, Sweden

4. 2010-03-01 to 2014-02-28:  Post Doc Researcher (Experimental Pathology, Dept of Translational Medicine) at Lunds universitet Medicinska fakulteten: Malmo, Skane, Sweden

AWARDS 

• First Prize- 'Innovative Research Award -2021' at 2nd HeriCure-Ukzn International Conference and Webinar, May 15-16, 2021.

• 'Dr. Bhagwati Prasad Innovative Research Award-2019' by Department of Biotechnology, Invertis University, Bareilly-2019.

• 'Early Career Research Award (ECRA)-2017' by Science and Engineering Research Board (SERB), Govt. of India in 2017.

• 'Young Scientist Award-2008' (Certificate & Cash Prize) from Society for Histochemistry, Europe- for the excellence in the field of Cell Biology & Pathology.

SELECTED PUBLICATIONS 

1: Kashyap A, Umar SM, Dev J R A, Prasad CP*. Dihydrotanshinone-I modulates Epithelial Mesenchymal Transition (EMT) Thereby Impairing Migration and Clonogenicity of Triple Negative Breast Cancer Cells. Asian Pac J Cancer Prev. 2021 Jul 1;22(7):2177-2184. doi: 10.31557/APJCP.2021.22.7.2177. PMID: 34319041. 

2: Umar SM, Patra S, Kashyap A, Dev J R A, Kumar L, Prasad CP*. Quercetin Impairs HuR-Driven Progression and Migration of Triple Negative Breast Cancer (TNBC) Cells. Nutr Cancer. 2021 Jul 19:1-14. doi: 10.1080/01635581.2021.1952628. Epub ahead of print. PMID: 34278888. 

3: Arundhathi JRD, Mathur SR, Gogia A, Deo SVS, Mohapatra P, Prasad CP*. Metabolic changes in triple negative breast cancer-focus on aerobic glycolysis. Mol Biol Rep. 2021 May;48(5):4733-4745. doi: 10.1007/s11033-021-06414-w. Epub 2021 May 28. PMID: 34047880. 

4: Umar SM, Kashyap A, Kahol S, Mathur SR, Gogia A, Deo SVS, Prasad CP*. Prognostic and therapeutic relevance of phosphofructokinase platelet-type (PFKP) in breast cancer. Exp Cell Res. 2020 Nov 1;396(1):112282. doi:                       10.1016/j.yexcr.2020.112282. Epub 2020 Sep 11. PMID: 32919954. 

5: Prasad CP, Manchanda M, Mohapatra P, Andersson T. WNT5A as a therapeutic target in breast cancer. Cancer Metastasis Rev. 2018 Dec;37(4):767-778. doi: 10.1007/s10555-018-9760-y. PMID: 30171384; PMCID: PMC6510844. 

6: Prasad CP*, Södergren K, Andersson T. Reduced production and uptake of lactate are essential for the ability of WNT5A signaling to inhibit breast cancer cell migration and invasion. Oncotarget. 2017 Apr 20;8(42):71471-71488. doi: 10.18632/oncotarget.17277. PMID: 29069720; PMCID: PMC5641063. 

7: Prasad CP*, Chaurasiya SK, Guilmain W, Andersson T. WNT5A signaling impairs breast cancer cell migration and invasion via mechanisms independent of the epithelial-mesenchymal transition. J Exp Clin Cancer Res. 2016 Sep 13;35(1):144. doi: 10.1186/s13046-016-0421-0. PMID: 27623766; PMCID: PMC5022188. 

8: Prasad CP*, Mohapatra P, Andersson T. Therapy for BRAFi-Resistant Melanomas: Is WNT5A the Answer? Cancers (Basel). 2015 Sep 17;7(3):1900-24. doi: 10.3390/cancers7030868. PMID: 26393652; PMCID: PMC4586801. 

9: Prasad CP*, Chaurasiya SK, Axelsson L, Andersson T. WNT-5A triggers Cdc42 activation leading to an ERK1/2 dependent decrease in MMP9 activity and invasive migration of breast cancer cells. Mol Oncol. 2013 Oct;7(5):870-83. doi: 10.1016/j.molonc.2013.04.005. Epub 2013 Apr 28. PMID: 23727359; PMCID: PMC5528454. 

10: Kumar A, Gupta R, Mathur N, Iyer VK, Thulkar S, Prasad CP, Das P, Rani L, Maqbool M, Shukla NK, Pal S, Sundar D, Sharma A. Microarray based gene expression profiling of advanced gall bladder cancer. Exp Oncol. 2020 Dec;42(4):277-284. doi: 10.32471/exp-oncology.2312-8852.vol-42-no-4.15476. PMID: 33355862. 

PUBLICATIONS (LINKS) 

Pubmed: https://pubmed.ncbi.nlm.nih.gov/?term=Prasad+CP&sort=date&size=50 

Google Scholar: https://scholar.google.com/citations?user=S0DacM0AAAAJ&hl=en